(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 September 2011 (15.09.2011)

PCT

(10) International Publication Number
WO 2011/110545 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 3/00* (2006.01)
A61K 31/4985 (2006.01) *A61P 25/00* (2006.01)

(21) International Application Number:
PCT/EP2011/053445

(22) International Filing Date:
8 March 2011 (08.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10155981.3 9 March 2010 (09.03.2010) EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BARTOLOMÉ-NEBREDA, José, Manuel** [ES/ES]; Janssen-Cilag S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **CONDE-CEIDE, Susana** [ES/ES]; Janssen-Cilag S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **MACDONALD, Gregor, James** [GB/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **PASTOR-FERNÁNDEZ, Joaquin** [ES/ES]; C/Hierbabuena 37, Urbanización La, Hacienda, Cobisa, E-45111 Toledo (ES). **VAN GOOL, Michiel, Luc, Maria** [BE/ES]; Janssen-Cilag S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **MARTÍN-MARTÍN, María, Luz** [ES/ES]; Janssen-Cilag S.A., Calle Jarama, 75 , Poligono Industrial, E-45007 Toledo (ES). **VANHOOF, Greta, Constantia, Peter** [BE/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA NV**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2011/110545 A1

(54) **Title**: IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES

(57) **Abstract**: The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.